Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

ovaries ovarian cancer

Lab receives $30M funding to illuminate lung and ovarian cancers

On Target Laboratories will use the funding to expand the market reach of its molecular imaging agent.

January 16, 2024

FDA approves radiopharmaceutical manufacturing site in Indianapolis

The new facility is run by Novartis and is being called the “most advanced of its kind."

January 8, 2024
Bhvita Jani, medical imaging principal analyst, Signify Research, discusses growing trend of theragnostics in nuclear imaging and oncology at RSNA2023. #theragnostics #RSNA #RSNA23 #RSNA2023 #radiology #NucMed #Oncology

Theragnostics: A growing trend in molecular imaging

Bhvita Jani, medical imaging principal analyst at Signify Research, discusses the evolution of theragnostics and its applications in nuclear imaging and oncology.

January 4, 2024

Pyrophosphate imaging agent shortage reported, could last weeks

Supply chain disruptions are blamed for the lack of production.

December 21, 2023
Damaged Organ

Pharmacy firm eyes 2024 rollout of 1st targeted PET imaging agent for kidney cancer

Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix). 
 

December 19, 2023
Brain MRI AI assessment and segmentation on Fujifilm's Synapse system at RSNA 2023. Photo by Dave Fornell. #RSNA #RSNA23 #RSNA2023

PHOTO GALLERY: New technology at RSNA 2023

Images from the world's largest radiology conference include new technologies and the latest advances in MRI, CT, nuclear medicine, X-ray, artificial intelligence, and PACS/enterprise imaging.

December 11, 2023
 International Workshop on Medical Radioisotopes Supply, October 2023

Medical radioisotope supply chain faces future crisis, Nuclear Energy Agency warns

Outdated infrastructure and a lack of young people entering the field are both impacting the security of critical isotopes such as molybdenum-99.

December 8, 2023
Siemens Healthineers Biograph Vision.X

FDA clears PET/CT scanner from Siemens Healthineers

The Biograph Vision.X is able to deliver an estimated 20% performance improvement, bolstering throughput while reducing radiotracer costs. 

November 27, 2023